{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:15:54Z","timestamp":1791123354685,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s11060-013-1055-0","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T16:31:35Z","timestamp":1359045095000},"page":"247-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases"],"prefix":"10.1007","volume":"112","author":[{"given":"Priya","family":"Kumthekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Avram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kaklamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Helenowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Rademaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Cianfrocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gradishar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Raizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,1]]},"reference":[{"issue":"6","key":"1055_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrclinonc.2011.58","volume":"8","author":"AF Eichler","year":"2011","unstructured":"Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK (2011) The biology of brain metastases-translation to new therapies. Nat Rev Clin oncol 8(6):344\u2013356","journal-title":"Nat Rev Clin oncol"},{"issue":"6","key":"1055_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/WCO.0b013e3283322a92","volume":"22","author":"MC Chamberlain","year":"2009","unstructured":"Chamberlain MC (2009) Leptomeningeal metastasis. Curr Opin Neurol 22(6):665\u2013674","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"1055_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3892\/or_00000564","volume":"22","author":"R Yamanaka","year":"2009","unstructured":"Yamanaka R (2009) Medical management of brain metastases from lung cancer (Review). Oncol Rep 22(6):1269\u20131276","journal-title":"Oncol Rep"},{"issue":"3\u20134","key":"1055_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10555-007-9083-x","volume":"26","author":"X Cheng","year":"2007","unstructured":"Cheng X, Hung MC (2007) Breast cancer brain metastases. Cancer Metastasis Rev 26(3\u20134):635\u2013643","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"1055_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11060-009-0060-9","volume":"96","author":"LE Gaspar","year":"2010","unstructured":"Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mikkelsen T, Olson JJ, Paleologos NA, Ryken TC, Kalkanis SN (2010) The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):17\u201332","journal-title":"J Neurooncol"},{"issue":"1","key":"1055_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11060-009-0073-4","volume":"96","author":"ME Linskey","year":"2010","unstructured":"Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Kalkanis SN (2010) The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):45\u201368","journal-title":"J Neurooncol"},{"issue":"1","key":"1055_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11060-009-0055-6","volume":"96","author":"M Ammirati","year":"2010","unstructured":"Ammirati M, Cobbs CS, Linskey ME, Paleologos NA, Ryken TC, Burri SH, Asher AL, Loeffler JS, Robinson PD, Andrews DW, Gaspar LE, Kondziolka D, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Patchell RA, Kalkanis SN (2010) The role of retreatment in the management of recurrent\/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):85\u201396","journal-title":"J Neurooncol"},{"issue":"3","key":"1055_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11060-005-9044-6","volume":"78","author":"AB Lassman","year":"2006","unstructured":"Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, Raizer JJ (2006) Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 78(3):255\u2013260","journal-title":"J Neurooncol"},{"issue":"4","key":"1055_CR9","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","volume":"16","author":"MJ Glantz","year":"1998","unstructured":"Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J clin 16(4):1561\u20131567","journal-title":"J clin"},{"issue":"4 Suppl 13","key":"1055_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0093-7754(01)90069-7","volume":"28","author":"LE Abrey","year":"2001","unstructured":"Abrey LE, Christodoulou C (2001) Temozolomide for treating brain metastases. Semin Oncol 28(4 Suppl 13):34\u201342","journal-title":"Semin Oncol"},{"issue":"2","key":"1055_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1023\/A:1008354323167","volume":"12","author":"C Christodoulou","year":"2001","unstructured":"Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV (2001) Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann oncol 12(2):249\u2013254","journal-title":"Ann oncol"},{"issue":"3","key":"1055_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1023\/A:1012226718323","volume":"53","author":"LE Abrey","year":"2001","unstructured":"Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG (2001) A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53(3):259\u2013265","journal-title":"J Neurooncol"},{"issue":"3","key":"1055_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s11060-011-0629-y","volume":"105","author":"NU Lin","year":"2011","unstructured":"Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP (2011) Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105(3):613\u2013620","journal-title":"J Neurooncol"},{"issue":"3","key":"1055_CR14","first-page":"256","volume":"24","author":"C Oberhoff","year":"2001","unstructured":"Oberhoff C, Kieback DG, Wurstlein R, Deertz H, Sehouli J, van Soest C, Hilfrich J, Mesrogli M, von Minckwitz G, Staab HJ, Schindler AE (2001) Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 24(3):256\u2013260","journal-title":"Onkologie"},{"issue":"3B","key":"1055_CR15","first-page":"2259","volume":"26","author":"V Lorusso","year":"2006","unstructured":"Lorusso V, Galetta D, Giotta F, Rinaldi A, Romito S, Brunetti C, Silvestris N, Colucci G (2006) Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell\u2019Italia Meridionale). Anticancer Res 26(3B):2259\u20132263","journal-title":"Anticancer Res"},{"issue":"12","key":"1055_CR16","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1158\/1078-0432.CCR-10-3095","volume":"17","author":"AM Tsimberidou","year":"2011","unstructured":"Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R (2011) Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res 17(12):4110\u20134118","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1055_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1215\/15228517-2007-059","volume":"10","author":"MD Groves","year":"2008","unstructured":"Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK (2008) A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-oncology 10(2):208\u2013215","journal-title":"Neuro-oncology"},{"issue":"2","key":"1055_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1054\/bjoc.2000.1574","volume":"84","author":"KA Jaeckle","year":"2001","unstructured":"Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O\u2019Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB (2001) Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84(2):157\u2013163","journal-title":"Br J Cancer"},{"issue":"11","key":"1055_CR19","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394\u20133402","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl","key":"1055_CR20","doi-asserted-by":"publisher","first-page":"258S","DOI":"10.1378\/chest.89.4_Supplement.258S","volume":"89","author":"RB Livingston","year":"1986","unstructured":"Livingston RB (1986) Current chemotherapy of small cell lung cancer. Chest 89(4 Suppl):258S\u2013263S","journal-title":"Chest"},{"issue":"5","key":"1055_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000227721","volume":"54","author":"G Samonis","year":"1997","unstructured":"Samonis G, Bafaloukos D, Margioris AN, Katsarma G, Toloudis P, Bacoyannis C, Karvounis N, Georgoulias V, Kosmidis P (1997) First-line chemotherapy of advanced breast cancer with a combination of mitoxantrone, methotrexate, and vincristine (MIMO). Oncology 54(5):371\u2013375","journal-title":"Oncology"},{"issue":"3","key":"1055_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-009-9940-2","volume":"95","author":"F Clatot","year":"2009","unstructured":"Clatot F, Philippin-Lauridant G, Ouvrier MJ, Nakry T, Laberge-Le-Couteulx S, Guillemet C, Veyret C, Blot E (2009) Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. J Neurooncol 95(3):421\u2013426","journal-title":"J Neurooncol"},{"issue":"1","key":"1055_CR23","first-page":"157","volume":"37","author":"HK Kimelberg","year":"1977","unstructured":"Kimelberg HK, Biddlecome SM, Bourke RS (1977) Distribution and degradation of [3H]methotrexate after intravenous and cerebral intraventricular injection in primates. Cancer Res 37(1):157\u2013165","journal-title":"Cancer Res"},{"issue":"3","key":"1055_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00277-008-0645-y","volume":"88","author":"YL Kwong","year":"2009","unstructured":"Kwong YL, Yeung DY, Chan JC (2009) Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann Hematol 88(3):193\u2013201","journal-title":"Ann Hematol"},{"issue":"2","key":"1055_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0360-3016(01)01639-X","volume":"51","author":"M Reni","year":"2001","unstructured":"Reni M, Ferreri AJ, Guha-Thakurta N, Blay JY, Dell\u2019Oro S, Biron P, Hochberg FH (2001) Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys 51(2):419\u2013425","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1055_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1592\/phco.26.5.641","volume":"26","author":"LR Villela","year":"2006","unstructured":"Villela LR, Stanford BL, Shah SR (2006) Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy 26(5):641\u2013654","journal-title":"Pharmacotherapy"},{"issue":"5","key":"1055_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1470-2045(00)00325-9","volume":"2","author":"NJ Curtin","year":"2001","unstructured":"Curtin NJ, Hughes AN (2001) Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol 2(5):298\u2013306","journal-title":"Lancet Oncol"},{"issue":"3","key":"1055_CR28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/annonc\/mdq400","volume":"22","author":"A Schneeweiss","year":"2011","unstructured":"Schneeweiss A, Marme F, Ruiz A, Manikhas AG, Bottini A, Wolf M, Sinn HP, Mansouri K, Kennedy L, Bauknecht T (2011) A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer. Ann Oncol 22(3):609\u2013617","journal-title":"Ann Oncol"},{"issue":"2","key":"1055_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10549-007-9722-5","volume":"110","author":"A Garin","year":"2008","unstructured":"Garin A, Manikhas A, Biakhov M, Chezhin M, Ivanchenko T, Krejcy K, Karaseva V, Tjulandin S (2008) A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 110(2):309\u2013315","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1055_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-010-1286-0","volume":"126","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Conkling PR, O\u2019Rourke MA, Kuefler PR, McIntyre KJ, Zhan F, Asmar L, Wang Y, Shonukan OO, O\u2019Shaughnessy JA (2011) Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat 126(1):101\u2013108","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1055_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3816\/CBC.2009.n.025","volume":"9","author":"M Martin","year":"2009","unstructured":"Martin M, Blasinska-Morawiec M, Salas JF, Falcon S, Rolski J, Ferrari BL, Gulyas S, Liu Y, Benhadji KA (2009) A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21\u00a0days in patients with advanced breast cancer. Clinical breast cancer 9(3):155\u2013160","journal-title":"Clinical breast cancer"},{"issue":"11","key":"1055_CR32","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S0959-8049(01)00117-4","volume":"37","author":"DW Miles","year":"2001","unstructured":"Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ (2001) A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 37(11):1366\u20131371","journal-title":"Eur J Cancer"},{"issue":"12","key":"1055_CR33","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1634\/theoncologist.2010-0224","volume":"15","author":"MH Cohen","year":"2010","unstructured":"Cohen MH, Cortazar P, Justice R, Pazdur R (2010) Approval summary: pemetrexed maintenance therapy of advanced\/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 15(12):1352\u20131358","journal-title":"Oncologist"},{"issue":"2","key":"1055_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.lungcan.2009.06.018","volume":"68","author":"A Bearz","year":"2010","unstructured":"Bearz A, Garassino I, Tiseo M, Caffo O, Soto-Parra H, Boccalon M, Talamini R, Santoro A, Bartolotti M, Murgia V, Berretta M, Tirelli U (2010) Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 68(2):264\u2013268","journal-title":"Lung Cancer"},{"issue":"3","key":"1055_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.lungcan.2009.03.019","volume":"65","author":"A Omlin","year":"2009","unstructured":"Omlin A, D\u2019Addario G, Gillessen S, Cerny T, von Hessling A, Fruh M (2009) Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer 65(3):383\u2013384","journal-title":"Lung Cancer"},{"issue":"4","key":"1055_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00280-006-0285-7","volume":"59","author":"SL Stapleton","year":"2007","unstructured":"Stapleton SL, Reid JM, Thompson PA, Ames MM, McGovern RM, McGuffey L, Nuchtern J, Dauser R, Blaney SM (2007) Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol 59(4):461\u2013466","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"1055_CR37","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/cncr.26709","volume":"118","author":"JJ Raizer","year":"2012","unstructured":"Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA (2012) Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma. Cancer 118(15):3743\u20133748","journal-title":"Cancer"},{"issue":"7","key":"1055_CR38","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277\u20131280","journal-title":"J Clin Oncol"},{"issue":"4","key":"1055_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Chaudhary A, Ghosh A, Johnson RD (2006) Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 57(4):401\u2013411","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1\u20132","key":"1055_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000069773","volume":"49","author":"S Vezmar","year":"2003","unstructured":"Vezmar S, Becker A, Bode U, Jaehde U (2003) Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49(1\u20132):92\u2013104","journal-title":"Chemotherapy"},{"issue":"2","key":"1055_CR41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/1078-0432.CCR-05-1834","volume":"12","author":"CJ Sweeney","year":"2006","unstructured":"Sweeney CJ, Takimoto CH, Latz JE, Baker SD, Murry DJ, Krull JH, Fife K, Battiato L, Cleverly A, Chaudhary AK, Chaudhuri T, Sandler A, Mita AC, Rowinsky EK (2006) Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Clin Cancer Res 12(2):536\u2013542","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1055_CR42","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1158\/1078-0432.CCR-09-3324","volume":"16","author":"NJ Dickgreber","year":"2010","unstructured":"Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK, Latz JE, Schneck KB, Yuan Z, Sanchez-Torres JM (2010) Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res 16(10):2872\u20132880","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1055_CR43","first-page":"545","volume":"1","author":"C Niyikiza","year":"2002","unstructured":"Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH, Allen RH (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1(7):545\u2013552","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1055_CR44","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1634\/theoncologist.12-7-808","volume":"12","author":"S Chattopadhyay","year":"2007","unstructured":"Chattopadhyay S, Tamari R, Min SH, Zhao R, Tsai E, Goldman ID (2007) Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 12(7):808\u2013815","journal-title":"Oncologist"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1055-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-013-1055-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1055-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1055-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T05:16:24Z","timestamp":1600751784000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-013-1055-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1007\/s11060-013-1055-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"1 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}